Your browser does not support iframes.
Regional Stocks
Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
NYSE COMPOSITE INDX
Gold
Crude Oil
BIOLINERX SP ADR
(NQ:
BLRX
)
1.750
USD
-0.030 (-1.69%)
Official Closing Price
/ Updated:
8:10 PM EDT, May 21, 2013
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Options
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Podcasts
Price and Volume
Detailed Quote
Intraday
1 Week
1 Month
3 Month
1 Year
Compare to:
None
S&P 500
Nasdaq
NYSE
AMEX
Russell 2000
Basic Materials
Conglomerates
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities
Volume
0
Open
1.780
Bid (Size)
1.740 (400)
Ask (Size)
1.760 (300)
Prev. Close
1.780
Today's Range
1.740 - 1.780
52wk Range
1.590 - 5.100
Shares Outstanding
22,255,386
Dividend Yield
N/A
Top News
More News
BioLineRx (BLRX) Enters $20M ATM Offering w/ Stifel
May 17, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8350563 for the full story.
Read More
from
StreetInsider.com News Articles
BioLineRx Enters into “At-The-Market” Offering Agreement with Stifel, Nicolaus & Company
May 17, 2013
from
Business Wire News Releases
More News
Read More
BioLineRx to Present at the Oppenheimer 14th Annual Israeli Conference on May 12th
May 09, 2013
from
Business Wire News Releases
BioLineRx Reports First Quarter 2013 Results
May 07, 2013
from
Business Wire News Releases
BioLineRx's BL-7010, for the Treatment of Celiac, to be Presented at Two Leading Conferences
May 02, 2013
from
Business Wire News Releases
BioLineRx to Report First Quarter 2013 Results on May 7, 2013
April 30, 2013
from
Business Wire News Releases
BioLineRx (BLRX) Enrolls First Patients in BL-8020 Phase I/II as HCV Treatment
April 29, 2013
from
StreetInsider.com News Articles
BioLineRx Enrolls First Patient in Phase I/II Clinical Trial for BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
April 29, 2013
from
Business Wire News Releases
Free Research Reports on APL, BLRX, INTC and OCZ Issued by the Bedford Report
April 18, 2013
from
Marketwired News Releases
BioLineRx to Present at the 12th Annual Needham Healthcare Conference in New York on April 30, 2013
April 18, 2013
from
Business Wire News Releases
Stock Market XML and JSON Data API
provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays.
Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Press Release Service
provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates
Bots go here
Your browser does not support iframes.